Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | HTT | P42858 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | ACHE | P22303 | 12/20 | 0.90 |
| ▸ | BCHE | P06276 | 9/20 | 0.90 |
| ▸ | BACE1 | P56817 | 2/20 | 0.90 |
| ▸ | GABRP | O00591 | 1/20 | 0.71 |
| ▸ | GABRD | O14764 | 1/20 | 0.71 |
| ▸ | APP | P05067 | 1/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.71 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.71 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.71 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.71 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.71 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.71 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.71 |
| ▸ | GABRE | P78334 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8022948 | 0.97 | MEN1 (0.97) | KDM4EMEN1HTTKMT2AACHE | |
| SCHEMBL15155625 | 0.89 | KDM4E (0.74) | KDM4EMEN1HTTKMT2AACHE | |
| SCHEMBL3361969 | 0.88 | KDM4E (0.72) | KDM4EMEN1HTTKMT2AACHE | |
| SCHEMBL29062227 | 0.88 | KDM4E (0.72) | KDM4EMEN1HTTKMT2AACHE | |
| SCHEMBL13480595 | 0.87 | BCHE (0.76) | ACHEBCHEBACE1GABRPGABRD | |
| SCHEMBL12043399 | 0.86 | BCHE (0.97) | ACHEBCHEBACE1GABRPGABRD | |
| SCHEMBL16223230 | 0.86 | ACHE (0.72) | KDM4EMEN1HTTKMT2AACHE | |
| SCHEMBL12043397 | 0.85 | BCHE (0.95) | ACHEBCHEBACE1GABRPGABRD | |
| SCHEMBL12043400 | 0.85 | BCHE (0.95) | ACHEBCHEBACE1GABRPGABRD | |
| SCHEMBL9257216 | 0.84 | ACHE (0.76) | KDM4EMEN1HTTKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012121998-A1 | BLOOD COLLECTION DEVICE CONTAINING LYSOPHOSPHOLIPASE INHIBITOR | BECTON, DICKINSON AND COMPANY (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | KDM4E 2095/4885MEN1 4080/4885HTT 2307/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | KDM4E 192/4885MEN1 3638/4885HTT 344/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | KDM4E 861/4885MEN1 4701/4885HTT 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.